EMA Withdrawn: Hepsera (adefovir dipivoxil) — Gilead Sciences Ireland UC

View source ↗

Summary

Hepsera (adefovir dipivoxil) has been withdrawn from the European market for chronic hepatitis B.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Hepsera (adefovir dipivoxil)

Snippet

Status: Withdrawn. Therapeutic area: Hepatitis B, Chronic. MAH: Gilead Sciences Ireland UC. Decision date: 20/04/2021